Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool November 19, 2010 Brian Orelli	One Drug, Two Names, Two Wildly Different Prospects Amgen double speaks for increased sales.
The Motley Fool December 14, 2010 Brian Orelli	An Ounce of Prevention, a Pound of Blockbuster Sales Amgen's Xgeva recently gained Food and Drug Administration approval to treat cancer patients that have bone metastasis.
The Motley Fool February 9, 2010 Brian Orelli	Bone Up On This Potential Blockbuster Amgen's denosumab passes another test on its way to potential blockbuster status.
The Motley Fool July 8, 2009 Brian Orelli	Amgen Closes In on a Home Run Amgen already had a ball flying high above the outfield in its osteoporosis treatment, denosumab, but yesterday's clinical trial results were the wind that could push it out of the park.
The Motley Fool August 14, 2009 Brian Orelli	Amgen Close to Scoring Big Amgen gets good-enough results from a FDA panel.
The Motley Fool May 18, 2011 Brian Orelli	More Data, Same Controversy Will Amgen's Xgeva be used to delay bone metastasis?
The Motley Fool October 22, 2009 Brian Orelli	Good Luck in 2010, Amgen Just when it looked like Amgen was turning things around the Food and Drug Administration threw a wrench in the biotech's plans for its osteoporosis drug Prolia.
The Motley Fool October 26, 2010 Brian Orelli	Thank Goodness for Amgen's New Kids The old drugs are dragging down Amgen's growth.
BusinessWeek January 14, 2010 Rob Waters	Amgen: Strengthening Bones, Weakening Cancer? Regulators may soon approve an Amgen drug, denosumab, for osteoporosis, but the payoff could be in oncology.
The Motley Fool January 25, 2011 Brian Orelli	2 Keys to Amgen's Continued Success Prolia and Xgeva have to perform.
The Motley Fool September 17, 2007 Brian Orelli	Preventing Cancer, No Bones About It For Eli Lilly, the only thing better than having a drug with more than $1 billion in annual sales is getting it approved to treat more patients. That's what just happened with their cancer drug, EVISTA. Investors, take note.
The Motley Fool October 19, 2009 Brian Orelli	Still Waiting for Its Blockbuster Amgen announces a Food and Drug Administration delay for its long-awaited osteoporosis drug, Prolia, its treatment for postmenopausal osteoporosis.
The Motley Fool June 2, 2010 Brian Orelli	Little Surprise. Big Stock Move. Investors like Amgen's early approval;shares are up 9% today, well ahead of the overall market.
The Motley Fool May 28, 2010 Brian Orelli	This Drug Doesn't Work. But All Is Not Lost. Novartis cancer drug fails one trial, but there's still hope.
The Motley Fool January 28, 2008 Brian Lawler	A Wing and a Prayer for Amgen Amgen announces data from its top pipeline drug candidate. Investors, take note.
The Motley Fool April 3, 2009 Brian Orelli	Pfizer + Sutent = One Exciting Roller Coaster This time on the down slope, unfortunately.
The Motley Fool October 25, 2011 Brian Orelli	Anemic Growth in All the Right Places Amgen's anemia drugs decline, but that's not its future anyway.
The Motley Fool June 4, 2010 Brian Orelli	This Cancer Drug's on a Roll Novartis' Afinitor scores another win.
The Motley Fool February 26, 2008 Brian Orelli	The Less-Flashy Prostate Cancer Treatment GTx shows off clinical trial data for a drug that counters the side effects of prostate cancer treatments.
BusinessWeek May 9, 2005 Catherine Arnst	Genentech's Lessons For Big Pharma The biotech company focuses on science -- not marketing, acquisitions, or patents.
The Motley Fool June 9, 2010 Brian Orelli	ASCO Pops and Drops Themes and company news from the annual meeting of the American Society of Clinical Oncology.
The Motley Fool April 28, 2009 Brian Orelli	Headline? Bad! Unexpected? No! For a company that only has one drug on the market, stopping a failing phase 3 clinical trial that's designed to expand the market of that drug is usually a major blow. But Onyx Pharmaceuticals was able to shrug it off.
The Motley Fool July 30, 2010 Brian Orelli	On the Path to a Blockbuster Amgen's Prolia will be a blockbuster. Eventually.
Pharmaceutical Executive October 1, 2008 Joanna Breitstein	The D-Mab Men Amgen's salvation just may be denosumab. We sit down to talk with the head scientists driving the drug for the multi-billion dollar osteoporosis market
BusinessWeek May 15, 2006 Arlene Weintraub	Rebuilding Amgen's Bones Amgen's mass-market osteoporosis drug could help reassure antsy investors.
BusinessWeek August 13, 2009 Arlene Weintraub	Amgen's Bone-Loss Drug Faces Marketing Hurdles Amgen is likely to receive FDA approval for denosumab, its new biologic bone-loss drug, but it may be a hard sell against cheaper generics.
The Motley Fool August 11, 2010 Brian Orelli	Amgen Comes Up a Little Short Amgen's drug Vectibix improves survival, but not by enough.
The Motley Fool July 24, 2009 Brian Orelli	Juicing Up the Earnings Report How did Celgene turn an earnings release that met analysts' expectations while lowering revenue guidance on one of its drugs into an 18.6% increase in share price yesterday?
The Motley Fool March 13, 2009 Brian Orelli	Pfizer Finally Gets a Hit! Positive results on Pfizer's cancer drug Sutent come earlier than expected.
The Motley Fool June 30, 2010 Brian Orelli	Which Midsized Biotech Is the Best Buy? Biogen Idec, Amgen, or Gilead? Which of these biotechs has the most potential for growth?
The Motley Fool March 30, 2010 Brian Orelli	Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers.
The Motley Fool February 9, 2011 Luke Timmerman	Amgen Pushes Ahead With "Son of Dmab" for Treating Bones Is there more to Amgen than "Dmab"?
The Motley Fool April 27, 2011 Brian Orelli	Falling Into the Zaltrap Lung cancer out, colon cancer in phase 3 clinical trial for Regeneron Pharmaceuticals' new drug.
The Motley Fool September 28, 2010 Brian Orelli	Pfizer's Sutent Fails. Again! No surprise here.
The Motley Fool November 21, 2008 Brian Orelli	Coughing Is Bad for Amgen's Health Safety concerns halt drug trial, but all is not lost.
The Motley Fool September 17, 2008 Brian Orelli	Will Denosumab Strengthen Amgen's Bones? Recently passing its phase 3 trial will help get denosumab on the market. But two big questions remain: how well it worked, and whether anyone will buy it, given the drug's plentiful rivals.
The Motley Fool December 6, 2007 Brian Lawler	Genentech Voted Down An FDA panel recommends against expanded use of Genentech's lead drug.
The Motley Fool July 6, 2009 Brian Orelli	Lilly Shows Us How It's Done The company announces that the Food and Drug Administration had expanded the approval of its cancer drug, Alimta, to include maintenance therapy for nonsquamous, non-small cell lung cancer.
BusinessWeek May 23, 2005 Catherine Arnst	If It Works for Breast Cancer... Studies are under way to see if promising strategies used against breast cancer can be used to fight other killers, such as lung, colon, and prostate cancer.
The Motley Fool January 7, 2010 Brian Orelli	Warning: Potential Anemic Growth Ahead Anemia-drug makers get more scrutiny from the FDA.
The Motley Fool February 25, 2008 Brian Lawler	A Positive Surprise for Genentech Biopharma Genentech's lead drug gets a conditional OK to treat breast cancer.
The Motley Fool June 15, 2010 Brian Orelli	Just Enough to Give Investors Hope Hitting a secondary endpoint means all is not lost for Onyx's lung cancer drug.
The Motley Fool May 28, 2009 Brian Orelli	Make Money, Fight Disease: The ASCO Preview The big cancer meeting is upon us.
The Motley Fool May 8, 2009 Brian Orelli	Investing Against Breast Cancer Many companies are interested in both a cure and a large lucrative market. Which are the best investments now in this sector?
The Motley Fool April 19, 2004 Charly Travers	4 Promising Biotech IPOs Several recently gone-public biotechs boast surprisingly interesting drug pipelines. From drugs for hepatitis to hopeful cancer treatments, watch out for these four biotech debutantes. If trials go smoothly, they may be the next up-and-coming stocks in the industry.
The Motley Fool March 30, 2011 Brian Orelli	Amgen's Long Shot Comes Up Short Amgen and Takeda Pharmaceutical's motesanib didn't extend overall survival in lung cancer patients when combined with Bristol-Myers Squibb's Taxol and carboplatin.
The Motley Fool June 6, 2011 Luke Timmerman	Exelixis Zeroes In on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients Is Exelixis' risky bet about to pay off?
BusinessWeek June 21, 2004 Catherine Arnst	Cancer Superdrugs, Costly Side Effects New therapies are extending lives, but the prices could weigh down the nation. Oncologists, pharmaceutical companies, and the government will have to focus on the best way to lower prices for these drugs.
The Motley Fool June 23, 2009 Brian Orelli	Wonder Drug! Maybe? Get the facts before jumping on this one.
The Motley Fool August 26, 2009 Brian Orelli	Amgen Falls Back on the Future Instead of the TREAT trial for Aranesp, Amgen's new cherry is Prolia's potential to treat cancer patients, for which Amgen could get marketing approval next year.